DWC202101

DWC202101 is a specific formulation of metformin developed by Daewoong Pharmaceutical for the treatment of type 2 diabetes mellitus. As a biguanide antidiabetic agent, it primarily works by inhibiting hepatic gluconeogenesis (glucose production in the liver), decreasing intestinal absorption of glucose, and improving insulin sensitivity by increasing peripheral glucose uptake and utilization. In clinical development, DWC202101 has been studied as the metformin component for co-administration with the SGLT-2 inhibitor enavogliflozin (DWP16001) to evaluate pharmacokinetic equivalence and safety compared to their fixed-dose combination product, DWJ1525 (brand name Envlomet).

Other names

metformin